View More Recent Stories
-
H.C. Wainwright Reiterates Buy Rating on BioHarvest Sciences (BHST)
-
BioHarvest Sciences Reports Fourth Quarter and Full Year 2024 Financial Results
-
BioHarvest Sciences to Host Fourth Quarter and Full Year 2024 Earnings Call on March 31 at 4:30 p.m. Eastern Time
-
BioHarvest Sciences to Participate in 37th Annual Roth Conference on March 16-18, 2025
-
BioHarvest In Vitro Testing Shows Proprietary Olive Cell Compound Reduces Fat Accumulation in Liver Cells
-
BioHarvest Sciences (BHST) Reports Sales of VINIA Now Exceed $50M
-
BioHarvest Announces Sales of Flagship Product VINIA Now Exceed $50 Million USD
-
BioHarvest Sciences to Present at WeBull Consumer Stocks Webinar on February 18
-
BioHarvest Sciences (BHST) Appoints Sharon Malka to its Board
-
BioHarvest Announces Appointment of Sharon Malka to Board of Directors
-
BioHarvest Sciences (BHST) Issues Shareholder Letter and Provides Corporate Update
-
BioHarvest Issues Shareholder Letter and Provides Corporate Update
-
Maxim Group Starts BioHarvest Sciences (BHST) at Buy
-
H.C. Wainwright Reiterates Buy Rating on BioHarvest Sciences (BHST)
-
Tate & Lyle and BioHarvest Announce Partnership to Drive the Future of Ingredients Through Botanical Synthesis Technology
-
BioHarvest Sciences Reports Third Quarter 2024 Financial Results
-
BioHarvest Launches VINIA SuperFood Functional Tea Line
-
BioHarvest Sciences to Participate in Noble Capital Markets Emerging Growth Conference on December 3, 2024
-
BioHarvest Sciences to Host Third Quarter 2024 Earnings Call on November 25 at 4:30 P.M. Eastern Time
-
BioHarvest Sciences (BHST) Begins Trading on Nasdaq
-
BioHarvest Sciences Begins Trading on the Nasdaq Global Market
